These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 26523411

  • 21. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS.
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [Abstract] [Full Text] [Related]

  • 22. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR.
    Blood Cancer J; 2017 Nov 27; 7(12):634. PubMed ID: 29176662
    [Abstract] [Full Text] [Related]

  • 23. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.
    Biol Blood Marrow Transplant; 2018 Aug 27; 24(8):1615-1620. PubMed ID: 29684564
    [Abstract] [Full Text] [Related]

  • 24. Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia.
    Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Christopeit M, Wolschke C, Bacher U, Kröger N.
    Transplant Cell Ther; 2022 May 27; 28(5):267.e1-267.e7. PubMed ID: 35066212
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.
    Leukemia; 2016 Jul 27; 30(7):1456-64. PubMed ID: 27012865
    [Abstract] [Full Text] [Related]

  • 27. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu J, Zhao XS, Liu YR, Xu LP, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Fan QZ, Huang XJ, Chang YJ.
    Chin Med J (Engl); 2018 Dec 05; 131(23):2808-2816. PubMed ID: 30511683
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Isolation of acute myeloid leukemia blasts from blood using a microfluidic device.
    Teixeira A, Sousa-Silva M, Chícharo A, Oliveira K, Moura A, Carneiro A, Piairo P, Águas H, Sampaio-Marques B, Castro I, Mariz J, Ludovico P, Abalde-Cela S, Diéguez L.
    Analyst; 2024 May 13; 149(10):2812-2825. PubMed ID: 38644740
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
    Reinhardt D, Langebrake C, Creutzig U, Vormoor J, Brune C, Thorwesten M, Ingiliz P, Hrusak O, Dworzak M, Griesinger F.
    Klin Padiatr; 2002 May 13; 214(4):179-87. PubMed ID: 12165899
    [Abstract] [Full Text] [Related]

  • 33. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR.
    Best Pract Res Clin Haematol; 2013 Sep 13; 26(3):279-84. PubMed ID: 24309531
    [Abstract] [Full Text] [Related]

  • 34. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C, Cazzaniga G, Coliva T, De Angelis C, Conter V.
    Expert Rev Anticancer Ther; 2011 Sep 13; 11(9):1391-401. PubMed ID: 21929313
    [Abstract] [Full Text] [Related]

  • 35. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
    Eckel AM, Cherian S, Miller V, Soma L.
    Cytometry B Clin Cytom; 2020 Mar 13; 98(2):174-178. PubMed ID: 31622025
    [Abstract] [Full Text] [Related]

  • 36. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
    Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW.
    Bone Marrow Transplant; 2000 Jan 13; 25(1):91-6. PubMed ID: 10654021
    [Abstract] [Full Text] [Related]

  • 37. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG, Zhao H, Sun XJ, He JJ, Su L, Xu J.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun 13; 17(3):557-62. PubMed ID: 19549363
    [Abstract] [Full Text] [Related]

  • 38. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
    Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A, Queipo de Llano MP, Sánchez JM, Brunet S, Sierra J, Spanish CETLAM Group.
    Leukemia; 2003 Jan 13; 17(1):76-82. PubMed ID: 12529663
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.